Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04394546 · ClinicalTrials.gov registry record · NA
CHAMPION-AF Clinical Trial
A NA study of Stroke and Atrial Fibrillation, sponsored by Boston Scientific Corporation.
- Active
- Registry status
- NA
- Development phase
- 3,000
- Enrollment target
- 20
- Study locations
NCT04394546: Active NA study of Stroke and Atrial Fibrillation, sponsored by Boston Scientific Corporation.
NCT04394546 is a NA study of Stroke and Atrial Fibrillation that is active but no longer recruiting, run by Boston Scientific Corporation. The registered enrollment target is 3,000 participants, below the 12,010-participant average among 454 other Stroke trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04394546, a NA study of Stroke and Atrial Fibrillation, is active but no longer recruiting, sponsored by Boston Scientific Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 3,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to determine if left atrial appendage closure (LAAC) with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation.
Primary Outcome
non-inferiority
Conditions Studied
Interventions
- DEVICE WATCHMAN FLX LAAC Device
- DRUG Non-Vitamin K Oral Anticoagulant
Study Locations (20)
California
- Sharp Chula Vista Medical Center - Chula Vista
- Marin General Hospital - Greenbrae
- Scripps Memorial Hospital - La Jolla
- Los Robles Hospital and Medical Center - Los Angeles
- El Camino Hospital - Mountain View
- Eisenhower Medical Center - Rancho Mirage
- Mercy General Hospital - Sacramento
- Santa Barbara Cottage Hospital - Santa Barbara
- St. John's Health Center - Santa Monica
Arizona
- Arizona Arrhythmia Research Center - Phoenix
- Phoenix Cardiovascular Research Group - Phoenix
- Scottsdale Healthcare - Shea - Scottsdale
- Tucson Medical Center Healthcare - Tucson
Alabama
- Grandview Medical Center - Birmingham
- University of Alabama at Birmingham - Birmingham
Arkansas
- Arrythmia Research Group - Jonesboro
Colorado
- Colorado Springs Cardiologist, P.C. - Colorado Springs
Connecticut
- Yale University School of Medicine - New Haven
Delaware
- Christiana Hospital - Newark
District of Columbia
- Washington Hospital Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2020-10-15 |
| Est. Completion | 2027-12 |
| Phase | NA |
What the registry record for NCT04394546 still lists
NCT04394546 is an interventional study that assigns participants to a tested intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus, below the 12,010-participant average among 454 other Stroke trials with a reported enrollment target (75% lower).
The record links to 3 conditions, with Stroke appearing as the primary indexed condition, and to 2 interventions - of which WATCHMAN FLX LAAC Device is the first listed.
NCT04394546 names 20 study sites across 8 states, led by California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT04394546 about?
NCT04394546 is a clinical study titled "CHAMPION-AF Clinical Trial". The primary objective of this study is to determine if left atrial appendage closure (LAAC) with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation.
What is the current status of trial NCT04394546?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 3,000 participants. The study started on 2020-10-15. Estimated completion is 2027-12.
What conditions does trial NCT04394546 study?
This clinical trial studies the following conditions: Stroke, Atrial Fibrillation, Bleeding.
What interventions are being tested in trial NCT04394546?
The interventions under investigation include: WATCHMAN FLX LAAC Device (DEVICE), Non-Vitamin K Oral Anticoagulant (DRUG).
Who is sponsoring clinical trial NCT04394546?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04394546 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04394546's enrollment target sits among peer trials
3,000 22nd of 454 higher than 432 of 454 other Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tracking a Tactile Signal Along the Nervous System
RECRUITING · NA
-
Transcranial Direct Current Stimulation (tDCS) With Verb Network Strengthening Treatment (VNeST) in Chronic Aphasia
RECRUITING · NA
-
Strategy Training for Individuals With Unilateral Neglect
RECRUITING · NA
-
Weight Loss and ExeRcise
RECRUITING · NA
-
Safety and Feasibility of an ExoNET for Supination Assistance for Stroke Survivors
RECRUITING · NA
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI